ArticleMolecules (Basel, Switzerland)2022
Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- "Journal of Parkinson's disease · 2026Review
- Dual Neuroprotective and Nephroprotective Effects ofInternational journal of molecular sciences · 2026Article
- A Comprehensive Review of the Therapeutic Potential of Mucuna Pruriens.Molecules (Basel, Switzerland) · 2026Review
- Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation ofCurrent drug targets · 2026Article
- Siddha medicine and modern neuroscience: a synergistic approach to neurological care.3 Biotech · 2025Review
- Drugs from poisonous plants: Ethnopharmacological relevance to modern perspectives.Toxicon: X · 2025Review
- Pathogenesis of testicular dysfunction in diabetes: exploring the mechanism and therapeutic interventions.Journal of assisted reproduction and genetics · 2025Review
- Neuropharmacological Interventions of Plant Origin for Parkinson's Disease: A Comprehensive Appraisal.Current neuropharmacology · 2025Review
- Review
- Article
- Japanese Mucuna pruriens (Hasshou Beans) Showed Fast-acting and Long-lasting Effects in Parkinson's Disease.Internal medicine (Tokyo, Japan) · 2024Article
- Article
- Article
- Effect ofFrontiers in physiology · 2023Article
- Development of Jelly Loaded with Nanogel Containing Natural L-Dopa fromPharmaceutics · 2022Article
- The Hepatoprotective and Anti-Nephrotoxic Potential of Methanolic Extract of a Polyherbal Preparation in CClDose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
Abstract
L-dopa, a dopaminergic agonist, is the gold standard for the treatment of Parkinson's disease. However, due to the long-term toxicity and adverse effects of using L-dopa as the first-line therapy for Parkinson's disease, a search for alternative medications is an important current challenge. Traditional Ayurvedic medicine has suggested the use of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.